From: Tazia Smith
Sent: 4/23/2014 11:54:04 AM
To: jeevacation@gmail.com
CC: richardkahn12@gmail.com; Paul Morris Nav Gupta ; Vinit Sahni
Vahe Stepanian
Subject: WY and Biotech K1
Attachments: pic25012.gif; pic20056.gif; pic27955.gif; pic15934.gif; pic28276.gif; 182298_20140422_20140423_1.pdf
Classification: Confidential
Jeffrey -
Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in
Gilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre -market
highs of $310, now —$303 (3-day chart below).
Just a reminder that your SY 102.5 call is going to expire 5/1. In speaking with Nay and vinit, they
looked at lot of weaker-yen iterations but their view is vols are too low and there is an absence of
catalysts to present a compelling trade at this moment to roll into; Nav will email you directly to
highlight entry points on a trade when he sees one. As you know, you've got your zero-cost option on for
some exposure to yen weakness.
(Embedded image moved to file: pic25012.gif)Source: Pershing, LAX and Bloomberg
(Embedded image moved to file: pic20056.gif)
Biogen - 3 -day inter-day chart
(Embedded image moved to file: pic2795S.gif)
(Embedded image moved to file: pic15934.gif)
Tazia Smith
Director I Key client Partners - us
DB Securities Inc
Deutsche Asset & wealth management
345 Park Avenue, 10154-0004 New York, NY, USA
Tel
Fax
mobile
Email
(Embedded image moved to file: pic28276.gif)
CONFIDENTIAL — PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0 101788
CONFIDENTIAL SDNY_GM_00247972
EFTA01447222